Researchers found extensive genetic overlap between OCD and chronic tic disorders, revealing shared disease mechanisms and potential treatment targets.
Real Simple on MSN
I have moral scrupulosity OCD—here’s what it’s like to question every thought and decision
Growing up religious, I was used to confessing my sins from a young age: “I was mean to my brother.” “I stole an extra cookie ...
The Mirror US on MSN
'I have to hide knives at home after OCD gave me thoughts of attacking my family'
Victoria Korlewala, 20, first began to have symptoms of obsessive-compulsive disorder — a mental health condition ...
Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...
Christopher Winrow, PhD, Recursion’s vice president of neuroscience, inside the company’s lab. Recursion marked a milestone in its up to $12 billion artificial intelligence (AI) collaboration with ...
On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...
Recursion Pharmaceuticals utilizes a proprietary operating system (OS) and an AI-powered algorithm that continuously runs virtual experiments, testing compounds against a library of human genes to ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results